Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
2022 · Nature Medicine · 162 citations
https://doi.org/10.1038/s41591-021-01677-z
J
Jingxian Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
112
Papers
1.7K
Citations
22
h-index
29
i10-index
Jingxian Liu is an academic researcher from Nanchang University. The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & Antibiotic Resistance in Bacteria & Viral-associated cancers and disorders. The author has an h-index of 22, co-authored 96 publications.
ORCID: 0000-0003-4194-5273Papers by this author
worksMulti-scale hybrid modified coatings on titanium implants for non-cytotoxicity and antibacterial properties
2021 · Nanoscale · 41 citations
https://doi.org/10.1039/d1nr02459k
Xuebijing injection reduces organ injuries and improves survival by attenuating inflammatory responses and endothelial injury in heatstroke mice
2015 · BMC Complementary and Alternative Medicine · 31 citations
https://doi.org/10.1186/s12906-015-0519-5
Rapid detection of carbapenemase activity of Enterobacteriaceae isolated from positive blood cultures by MALDI-TOF MS
2018 · Annals of Clinical Microbiology and Antimicrobials · 31 citations
https://doi.org/10.1186/s12941-018-0274-9
Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor
2019 · Scientific Reports · 21 citations
https://doi.org/10.1038/s41598-019-54231-w
A risk score based on pediatric sequential organ failure assessment predicts 90-day mortality in children with Klebsiella pneumoniae bloodstream infection
2020 · BMC Infectious Diseases · 14 citations
https://doi.org/10.1186/s12879-020-05644-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat